Investor Update
Basel 19 October 2009
Genentech and Biogen Idec Receive a Complete Response from FDA for Earlier Use of Rituxan for Rheumatoid Arthritis
Dear Investor,
Please find attached a press release issued by Genentech and Biogen Idec in the US with respect to the approval of Rituxan in early and late stage rheumatoid arthritis in the US.